Key facts
- Conformal’s last known valuation is $316.0M (Jul 2025).
- It has raised $165.9M; the latest was Merger/Acquisition ($67.0M) in Feb 2026.
- Notable investors include Fidelity Management & Research Company, The Ropart Asset Management Funds, Angel Physicians Fund, Catalyst Health Ventures, Excelestar Ventures — 6 tracked in total.
- Status: Acquired/Merged (Operating Subsidiary).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Conformal
- ·The full record, as it builds
Funding rounds
No funding rounds for Conformal are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Conformal
Developer of a medical implant device designed to prevent stroke in patients with atrial fibrillation. The company's device addresses non-valvular atrial fibrillation and tailors its design to each patient's anatomy, meeting the demands of atrial appendage closure, enabling doctors and medical professionals to treat patients prone to strokes and save lives.
- Sector
- Healthcare
- HQ
- Nashua, NH, United States
- Founded
- 2016
- Employees
- 48
- Website
- conformalmedical.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
Conformal doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Conformal shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Conformal in its N-PORT filings yet. We sweep new filings monthly.